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ABSTRACT
Histone tail modifications control many nuclear
processes by dictating the dynamic exchange
of regulatory proteins on chromatin. Here we
report novel insights into histone H3 tail struc-
ture in complex with the double PHD finger
(DPF) of the lysine acetyltransferase MOZ/
MYST3/KAT6A. In addition to sampling H3 and
H4 modification status, we show that the DPF
cooperates with the MYST domain to promote
H3K9 and H3K14 acetylation, although not if
H3K4 is trimethylated. Four crystal structures
of an extended DPF alone and in complex with
unmodified or acetylated forms of the H3 tail
reveal the molecular basis of crosstalk between
H3K4me3 and H3K14ac. We show for the first
time that MOZ DPF induces a-helical conform-
ation of H3K4-T11, revealing a unique mode of
H3 recognition. The helical structure facilitates
sampling of H3K4 methylation status, and proffers
H3K9 and other residues for modification.
Additionally, we show that a conserved double
glycine hinge flanking the H3 tail helix is
required for a conformational change enabling
docking of H3K14ac with the DPF. In summary,
our data provide the first observations of exten-
sive helical structure in a histone tail, revealing
the inherent ability of the H3 tail to adopt alter-
nate conformations in complex with chromatin
regulators.
INTRODUCTION
Histone N-terminal tails are subject to multiple
posttranslational modiﬁcations (PTMs) that can modify
chromatin structure and act as signals to recruit, evict or
repel chromatin regulators. Thus, histone PTMs constitute
a combinatorial ‘semaphore’ that demarcates genomic
regions for activation, repression, repair or other processes
(1). Chromatin regulatory complexes can establish or erase
these signals through their enzymatic activities, and many
contain reader domains that enable them to recognize
selected histone PTMs (2). Dynamic changes in histone
PTMs reﬂect the expression status of genes and their regu-
latory regions, thus the ability of chromatin regulators to
recognize combinatorial heterotypic PTMs in their histone
substrates is essential to their function. Supporting evidence
for this model comes from structural studies of histone tail
recognition by the tandembromodomains of bromodomain,
testis speciﬁc (BRDT) (3), the plant homeodomain (PHD
ﬁnger) and double tudor domains of ubiquitin-like with
PHD ﬁnger and RING domains 1 (UHRF1) (4) and the
dual PHD/Bromo domains of bromodomain PHD ﬁnger
transcription factor (BPTF) (5). A systematic study of the
interactions of bromodomains with acetylated histone
peptides suggests that multivalent recognition of PTMs is
an important and widespread function of chromatin
readers (6). This sampling functionality is likely to
underpin crosstalk between different histone PTM signals,
facilitating recruitment and dismissal of chromatin regula-
tors to drive genomic processes. Understanding these
processes at the molecular level will be essential for
devising new therapeutic interventions in human diseases
such as cancer, in which chromatin functions are disrupted.
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The developmental regulator monocytic leukaemia zinc
ﬁnger protein (MOZ) also known as (MYST3/KAT6A) is
a MYST (Moz, Ybf, Sas, TIP60) family acetyltransferase
that is required for self-renewal and differentiation of
haematopoietic stem cells (7). MOZ appears to function
as a cofactor for AML1, Pu.1 and p53-mediated gene ex-
pression (8–10). Recurrent translocations within the MOZ
gene are associated with acute leukaemia, producing onco-
genic MOZ fusion proteins that can induce leukaemia in
animal models (11,12). Fusion proteins such as
transcriptional intermediary factor 2 (MOZ-TIF2) retain
the N-terminal portion of MOZ and show aberrant func-
tionality, which impacts on histone modiﬁcation and gene
regulation (8,10,13).
In addition to the MOZ acetyltransferase domain
(referred to as the MYST domain), the N-terminus of
MOZ contains two tandem PHD ﬁngers comprising the
double PHD ﬁnger (DPF) domain (Figure 1A). While
PHD2 shares homology with numerous other PHD
ﬁngers, PHD1 is distinctive, showing closest homology
with MOZ related factor (MORF)/MYST4 and the
BRG1 associated factor (BAF) complex components
DPF1/BAF45b/neuro-d4, DPF2/BAF45d/ubi-d4, DPF3/
BAF45c/cer-d4 and PHF10/BAF45a, all of which
contain a similar tandem PHD ﬁnger arrangement (for
sequence alignment, see Figure 5D). The DPF3b isoform
was shown to have acetyl histone-binding function (14),
and a subsequent nuclear magnetic resonance structure
revealed how its PHD ﬁngers function together to
achieve combinatorial recognition of unmodiﬁed H3K4
and acetylated H3K14 (15). The H3 tail in these solution
structures adopted an extended conformation as has been
observed for H3 and H4 histone tail peptides in complex
with other PHD domains (16) (see Figure 5B and E).
MOZ also binds acetylated histone H3 tails (17,18)
and a crystal structure in complex with an H3 peptide-
reported DPF interactions with the ﬁrst ﬁve residues
of H3 (18). However, how MOZ engages the H3 tail to
interpret its methylation/acetylation status remains poorly
understood.
In this study, we report a series of four crystal structures
of an extended MOZ DPF domain alone and in complex
with the H3 N-terminal tail, including unmodiﬁed,
H3K9ac and H3K14ac forms providing detailed novel
insights into the consequences of PTM on H3 tail struc-
ture in complex with a DPF. The MOZ DPF domain is
expanded in comparison with other studies to include a
sequence at the N-terminal boundary that is highly
conserved in MORF/MYST4/KAT6B. We show that the
H3 N-terminus can adopt signiﬁcant a-helical conform-
ation in complex with a chromatin regulator, which has
not been observed previously. The structures combined
with biochemical studies reveal how MOZ DPF manipu-
lates the structure of the H3 tail to sample its modiﬁcation
status and promote its acetylation. The structures also
show that docking of H3K14ac with the DPF depends
on a double glycine hinge (G12–G13) in H3 that can
undergo a conformational change. These results provide
new insights into histone tail recognition and acetylation
by MOZ, crosstalk between heterotypic histone modiﬁca-
tions and reveal novel structural features of the H3
N-terminus and its inherent conformational adaptability
in complex with chromatin regulators.
MATERIALS AND METHODS
Expression constructs, peptides, antibodies
Glutathione-S-transferase (GST)-fusion constructs MOZ
(1–321); MOZ DPF (194–323); MOZ PHD1 (194–265);
MOZ PHD2 (250–323); MOZ MYST (510–810); MOZ
DPF-MYST (194–810) and MORF DPF (210–330) were
constructed by polymerase chain reaction (PCR)
subcloning into the vector pGEX-DMH (19). The expres-
sion construct His-MOZ DPF (194–323) was generated by
PCR subcloning into the XhoI and BamHI sites in pET15b
vector (Novagen). FLAG-MOZ full-length (1–2004) and
FLAG MOZ-N (1–1117) have been described previously
(10). Biotin-conjugated histone peptides were purchased
from Millipore and Peptide Protein Research Ltd. Calf
thymus core histone preparations were purchased from
Sigma or Roche. Antibodies a-GST (G7781) and a-
FLAG M2 (F3165) were from Sigma; a-MOZ (KAT6A-
61327) was from Active Motif; a-H2A (ab18255), a-H2B
(ab1790), a-H3 (ab1791), a-H4 (ab10158), a-H3K9ac
(ab4441), a-H3K9me3 (ab8898) and a-H3K4me3
(ab8580) were from Abcam; and a-H3K14ac (20) was a
gift from Laszlo Tora.
Protein expression and puriﬁcation
His-tagged MOZ DPF recombinant protein was expressed
in Escherichia coli Rosetta 2. Cultures were grown at
37C, followed by induction with 0.1mM Isopropyl b-
D-1-thiogalactopyranoside (IPTG) for 16 h at 22C. Cell
pellets were resuspended in binding buffer (0.02M sodium
phosphate, 0.5M NaCl, pH 7.4), sonicated and the soluble
protein was harvested by centrifugation. Recombinant
protein was puriﬁed on a HiTrap chelating column
preloaded with NiSO4. The column was equilibrated
with binding buffer, loaded with the protein sample and
washed with binding buffer containing 5mM imidazole.
His-tagged MOZ DPF was then eluted in binding buffer
containing 300mM imidazole and the His-tag removed by
incubation with thrombin overnight at 22C. The
untagged MOZ DPF was puriﬁed to homogeneity on a
Superdex 75 16/60 gel ﬁltration column (GE Healthcare)
using 50mM Tris–Cl, pH 7.6, 150mM NaCl, 1mM
dithiothreitol (DTT) as running buffer.
Recombinant GST-tagged MOZ was produced in
Rosetta cells. Cultures were grown at 37C and recombin-
ant protein production was induced using 0.3mM IPTG
for 3–16 h at 20, 30 or 37C (conditions optimized for each
construct). Cells were harvested, resuspended in NTN
buffer (20mM Tris–HCl, pH 8.0, 100–500mM NaCl,
0.5% NP-40), sonicated and the soluble protein harvested
by centrifugation. Recombinant proteins were puriﬁed
on glutathione sepharose beads (GE Healthcare) on a
rotating wheel overnight at 4C. The beads were collected
by centrifugation and GST-fusion proteins eluted with
glutathione buffer. The samples were ﬁnally desalted and
buffer exchanged using PD-10 desalting columns
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Figure 1. MYST DPFs function in histone acetylation and PTM recognition. (A) MOZ/MYST3 domain structure showing the NEMM (N-terminal
domain of Enoki, MOZ and MORF); DPF; and MYST domains, the latter of which combines a zinc ﬁnger (Zn) and HAT domain. Regions rich in
serine (S), proline and glutamine (P/Q), methionine (M) or acidic residues are also indicated. Approximate boundaries of GST-fusion proteins used
for in vitro assays are also indicated. (B) MOZ DPF domains sense H3 and H4 PTMs. In vitro binding assays showing the interaction of puriﬁed
GST fusion proteins with immobilized biotinylated H3 and H4 peptides, either unmodiﬁed or bearing speciﬁc modiﬁcations, as indicated. Afﬁnity
capture of recombinant GST-MOZ DPF proteins on histone peptides is detected by western blotting using a-GST antibody. (C) Effect of H3
acetylation on binding of GST MOZ DPF (D) MOZ DPF enhances histone acetylation by the MYST domain. In vitro HAT assays showing rates of
acetylation of core histones by equimolar amounts of MOZ MYST domain (510–810) or the combined DPF-MYST (194–810). The data represent
the mean of replicates and error bars show standard deviations. (E) MOZ DPF-MYST acetylates H3K14 and H3K9. Immunodetection of H3K9ac
and H3K14ac after treatment of unmodiﬁed H3 with GST-MOZ-DPF, or GST control. (F) In vitro HAT assays showing acetylation of unmodiﬁed
H3, H3K9ac and H3K14ac peptides by MOZ DPF-MYST domain, or control. (G) Acetylation of H3 and H4 peptides by MOZ PHD2, MOZ
MYST or MOZ DPF-MYST proteins or control. Data columns appear in order listed in the key. (H) H3 tail acetylation enhances binding by MOZ
DPF-MYST. Binding assays of GST MOZ DPF-MYST to unmodiﬁed H3 in the presence 0, 1.5 or 3 mM acetyl CoA. Proportion of afﬁnity captured
DPF-MYST proteins relative to input was quantiﬁed by densitometry.
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(Sephadex TM G-25 medium, GE Healthcare) and
concentrated using Vivaspin concentrators (Sartorius).
Histone binding, acetylation assays, chromatin IP
For histone peptide binding assays 1.5mg of puriﬁed
GST-tagged fusion protein was incubated with 1.5mg of
biotin-conjugated histone peptides (Millipore/Peptide
Protein Research) or no peptide as control, overnight with
rotation at 4C. Dynabeads (M-280 Streptavidin-
Invitrogen) were pre-washed twice in 1 phosphate
buffered saline (PBS) containing 0.1% Tween 20 and 20ml
added to each reaction for 1 h at 4C. Acetyl CoA (1.5 or
3mM)was added if required. The beads were harvested using
a magnet and washed (3 10min) in binding buffer.
Following sodiumdodecyl sulphate-polyacrylamide gel elec-
trophoresis (SDSPAGE), bound proteins were visualized by
immunodetection with a-GST, and quantiﬁed by densitom-
etry using image J software, as required. Similarly, peptide
binding assays were performed with normalized amounts of
in vitro translated 35[S] methionine-labelled FLAG-MOZ
proteins, with bound protein visualized by autoradiography.
Alternatively, core histones (10mg) were added to GST pull-
downs and bound histones detected by immunoblot using
speciﬁc antibodies.
For acetylation assays, 1.5mg of puriﬁed GST or GST-
MOZ proteins was mixed with 10 mg of core histones
or 0.75 mg of histone peptide in 40 ml of histone
acetyltransferase (HAT) buffer containing 5 mg of bovine
serum albumin. Samples were incubated for 2min at 30C
before the addition of 1.8 ml of radiolabelled acetyl-CoA
[3H] (15.4 mM). Reactions were stopped after 30min by ad-
justing to 1 SDS PAGE loading buffer and boiling for
2min. Control reactions to ascertain background included
histones only, and GST-MOZ proteins without histones.
Incorporation of acetyl[3H] in histones or histone peptides
was measured in triplicate by scintillation counting.
Activity was expressed as the fold increase in decays per
minute over control. For kinetic assays, reactions were
stopped at the indicated times and expressed as pmoles
acetyl[3H] incorporated/pmole GST-MOZ protein. To
detect speciﬁc acetylation events (H3K9ac; H3K14ac) by
western blots, HAT assays were performed as above but
with unlabelled acetyl-CoA and spotted onto nitrocellulose
ﬁlters before immunoblotting with speciﬁc antibodies.
For chromatin IP, K562 cells were grown in RPMI sup-
plemented with foetal bovine serum. Approximately
1.5 107 cells were ﬁxed with 1% formaldehyde for
8min at room temperature and subsequently quenched
with 0.125M glycine. Cells were washed three times with
ice-cold PBS, resuspended in cell lysis buffer [5mM Tris–
Cl (pH 8.0), 85mM KCl, 0.5% NP-40] and incubated for
10min on ice. Chromatin was extracted from nuclear
pellets using a chromatin immunoprecipitation (ChIP)-
IT kit (Active Motif). The sample was sonicated using a
Diagenode water bath sonicator under conditions
optimized to give a DNA fragment length of 200–
500 bp. DNA content was measured using a bioanalyser
(Agilent) and fragment size veriﬁed by gel analysis.
Immunoprecipitation was performed with PureProteome
magnetic beads (Millipore) as per manufacturer’s
protocol. Approximately 10 mg of chromatin was used
for each IP, which was incubated with 5 mg of a monoclo-
nal a-MOZ antibody (a-KAT6A) overnight at 4C. The
beads were washed three times for 10min with 1 PBS-
Tween and the immunoprecipitate was eluted by 60 ml
SDS PAGE loading buffer (X4). Samples were boiled
for 10min, removed from beads and processed by SDS
PAGE. Immunoblots were then performed to detect for
enrichment of speciﬁc histone PTMs.
Crystallization, data collection and structure solution
Pure MOZ DPF fractions were concentrated to 9.4mg/ml
and subjected to crystallization trials. An aliquot of the
sample was mixed in a 1:1.5 molar ratio with N-terminal
histone H3 peptide spanning residues 1–21, incubated on
ice for 30min and set up for co-crystallization trials. Large
single crystals grew after 3 days with 100mM Na-Hepes,
pH 7.5, 1.4M sodium citrate as precipitant solution. Single
crystals were ﬂash cooled in liquid nitrogen using ethylene
glycol as cryoprotectant. Crystals have the symmetry of
space group P43212 with cell parameters of
a=b=70.52 A˚, c=96.83 A˚. A high resolution data set
was collected at the European Synchrotron Radiation
Facility (ESRF), France, beam line ID23-2 at a wavelength
of 0.8726 A˚ and at cryogenic temperatures. Data collection
and reﬁnement statistics are summarized in Table 1. The
structure was solved by single-wavelength anomalous dis-
persion (SAD) using the anomalous signal from the zinc
atoms. Crystals of MOZ DPF in complex with H3K9ac
were obtained under equivalent conditions as the unmodi-
ﬁed H3 complex crystals. Data to 1.6 A˚ resolution were
collected at the ESRF, beamline ID-29. Apo crystals of
MOZ DPF grew in 1:1 ratio of protein solution to
mother liquor comprising 60% tacsimate, pH 7
(Hampton Research, USA), at room temperature.
Crystals were transferred to a solution of 80% tacsimate
supplemented with 10% glycerol before ﬂash cooling.
A data set to 3 A˚ resolution with unit cell parameters of
a=b=64.69 A˚, c=64.80 A˚ and space group P 31 2 1 was
collected at the ESRF, France, beam line ID23-2 at a wave-
length of 0.8726 A˚. Crystals of MOZ DPF in complex with
H3 K14ac grew in 0.2M Li2SO4, 0.1M Tris–Cl, pH 8.5,
and 30% PEG 4000 after 2 months. Crystals have the
symmetry of space group C2, unit cell parameters
a=138.72 A˚, b=32.20 A˚, c=74.87 A˚, b=94.36. A
data set at 100K at a wavelength of 0.91732 A˚ was collected
at Diamond Light Source (DLS, Oxford, UK) beamline
I04-1. The MOZ DPF and DPF–H3 complex structures
were solved by molecular replacement with the program
PHASER using the model generated from the DPF–H3
complex SAD experiment as a search model (21).
Model building and structure reﬁnement
After density modiﬁcation, model building of the MOZ
DPF–H3 complex structure was straight forward and was
performed using a combination of automatic model
building (RESOLVE) and manual rebuilding and adjust-
ments in COOT (22). The structure was reﬁned to a ﬁnal
crystallographic Rfactor of 16.5% and Rfree of 18.6%
using the PHENIX suite of programs (23). Ninety-eight
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percent of residues were in the favoured regions of
the Ramachandran plot and 2% in the allowed regions.
The DPF in complex with H3K9ac was reﬁned to an
Rfactor of 16.5% and Rfree of 18.5%, with 98% of
residues in the preferred and 2% of residues in the
allowed regions of the Ramachandran plot. The unbound
MOZ DPF crystal structure was reﬁned to a ﬁnal Rfactor
of 23.9% and Rfree of 25.5%, respectively. Ninety-ﬁve
percent of residues were in preferred regions and 5% of
residues in the allowed regions. In this structure, residues
270–273 were poorly deﬁned in the electron density and
therefore not modelled. MOZ DPF in complex with
H3K14ac was reﬁned to a ﬁnal Rfactor of 21.9% and
Rfree of 26.6%. In the ﬁnal model, 95% of residues were
in the preferred regions and 5% of residues were in the
allowed regions of the Ramachandran plot. All steps of
reﬁnement were carried out using the PHENIX suite
using a maximum likelihood target and non-
crystallographic symmetry (NCS) restraints where applic-
able (23). After each round of reﬁnement electron density
maps were inspected visually and the models manually
adjusted in COOT (22). The geometry and overall quality
of the structures was assessed using MOLPROBITY (24).
RESULTS
The MOZ DPF binds H3 and H4 N-terminal tails and
samples their PTM status
MOZ is a multidomain chromatin-associated protein con-
taining a lysine acetyltransferase (MYST) domain, and an
adjacent tandem DPF domain, as shown schematically
in Figure 1A. Using a series of GST-MOZ constructs
(Figure 1A; Supplementary Figure S1A), in vitro binding
assays established that the DPF domain of MOZ interacts
directly with histone H3 (Supplementary Figure S1B).
Peptide surrogates demonstrated that this interaction is
mediated by the H3 N-terminal tail, as MOZ DPF
showed a robust interaction with H3 (1–21) (Figure 1B),
but not H3 (22–44) (Supplementary Figure S1C).
Association of MOZ DPF with H3 tail peptides was
reduced by mono- or dimethylation of H3K4 and com-
pletely blocked by H3K4me3, whereas binding to peptides
containing methylated forms H3K9 was tolerated
(Figure 1B; Supplementary Figure S1D). We did not
detect binding to peptides containing H3K27me1 or
H3K36me1, consistent with the lack of interaction of
MOZ DPF with this region of H3 (Supplementary
Figure S1C and D). Western blots conﬁrmed that the
MOZ DPF can associate with H3 histones containing
the repressive modiﬁcation H3K9me3, but not
H3K4me3 (Supplementary Figure S1E). Consistent with
this result, recombinant full-length FLAG-MOZ protein,
or the N-terminal portion of MOZ that is retained in
leukaemogenic fusion proteins (FLAG-MOZ-N: 1-1117)
(10) showed robust binding to unmodiﬁed H3 or
H3K9me3 peptides, but not H3K4me3 (Supplementary
Figure S1F). These binding patterns are consistent with
other recent studies (17,18) and indicate a role for the
DPF in sampling H3K4 methylation status, whereas
H3K9 methylation did not appear to have a major inﬂu-
ence on the MOZ DPF/H3 interaction interface.
Table 1. Data collection and reﬁnement statistics
Data set MOZ DPF MOZ DPF–H3 (SAD data set) MOZ DPF–H3 K9ac MOZ DPF–H3 K14ac
Data collection
Space group P 31 2 1 P 43 21 2 P 43 21 2 C 2
Cell parameters
a, b, c (A˚) 64.69 64.69 64. 80 70.52 70.52 96.83 70.46 70.46 96.37 138.72 32.20 74.87
a, b, g () 90 90 120 90 90 90 90 90 90 90 94.36 90
Resolution (A˚) 56–3.0 (3.16–3.00) 57.0–1.6 (1.79–1.6) 48.19–1.61 (1.64–1.61) 29.1–2.5 (2.64–2.5)
Rmerge (%) 7.4 (70) 5.7 (47.3) 7.6 (86.2) 15.7 (32)
I/sI 14.9 (2.7) 16.8 (3.6) 19.6 (2.8) 12.4 (3.8)
Completeness (%) 99.7 (99.3) 99.7 (99.7) 100 (100) 99.6 (98.3)
Redundancy 4.5 (4.6) 4.9 (5.0) 11 (10.5) 9.5 (4.1)
Reﬁnement
Resolution (A˚) 56.0–3.0 49.9–1.6 44.3–1.6 29.1–2.5
Number of reﬂections 3686 32739 32092 11577
Rwork (%)/Rfree (%) 23.9/25.5 16.5/18.6 16.5/18.5 21.9/26.6
Number of atoms 945 1234 1267 2283
Protein 935 1070 1105 2127
Ligand/ion 4 4 4 8
Water 6 160 158 148
Average B-factors (A˚2)
Protein 84.1 26.2 35.7 41.4
Ligand/ion 79.0 19.3 25.6 32.5
Water 62.4 33.8 44.1 45.9
RMSD
Bond lengths (A˚) 0.004 0.017 0.008 0.005
Bond angles () 1.09 1.58 1.26 0.903
Ramachandran
Favoured region (%) 95 98 98 95
Allowed region (%) 5 2 2 5
Values in parentheses correspond to the highest-resolution shell.
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The MOZ DPF domain also displayed a weaker ability
to bind the H4 (2–24) N-terminal tail peptide, but not
when the tail peptide was hyperacetylated (Figure 1B;
Supplementary Figure S1G). Acetylation of H4K5,
H4K8, H4K12 or H4K16, alone or in combination,
completely abrogated binding to MOZ proteins
(Supplementary Figure S1G). These results demonstrate
an important difference between MOZ and DPF3b/
BAF45c protein, as the latter was reported to show
enhanced binding to H4 when K16 is acetylated (15).
In contrast to H4 acetylation, H3 tail peptides contain-
ing H3K9/14Ac showed enhanced recruitment of the
MOZ DPF (Figure 1B), and further analysis indicated
that acetylation of H3K14 stabilizes the binding of the
H3 tail to MOZ DPF (Figure 1C). To further support
these in vitro binding data, FLAG-MOZ protein was
transiently expressed in U2OS cells for immunoﬂuores-
cent staining. FLAG-MOZ showed a typical punctate
nuclear stain as previously reported (10,13) and showed
substantial co-localization with pan-acetyl histone H3
and H3K9me3 staining patterns (Supplementary
Figure S2A). However, FLAG-MOZ foci overlapped
poorly with H3K4me3 staining. Cross-linked chromatin
was prepared from K562 leukaemic cells, which express
high levels of MOZ, and subjected to immunoprecipitation
with a-MOZ antibody or IgG control. As shown in
Supplementary Figure S2B, western blots conﬁrmed that
MOZ-bound chromatin is enriched in H3K14Ac, but not
H3K4me3. Taken together, these results indicate that
MOZ associates with chromatin containing distinctive
histone PTM signatures, i.e being enriched where there
is acetylated H3, but largely excluded from H3K4me3-
enriched chromatin. Thus, while acetylation of H3K14
stabilizes interaction of MOZ with H3, H4 acetylation
may have opposing effects on MOZ recruitment.
Consistent with these results, the DPF domain of
MORF/MYST4 showed highly similar H3 PTM binding
preferences (Supplementary Figure S1H).
To assess the contribution of the individual PHD
domains of MOZ in binding to histone tails, we generated
GST-PHD1 and GST-PHD2 constructs (Supplementary
Figure S1A). The PHD1 and PHD2 subdomains displayed
differential histone binding properties. PHD1 showed
little interaction with any H3 peptides, but was capable
of binding to unmodiﬁed H4 N-terminus (Supplementary
Figure S1I). As observed for both the MOZ DPF domain
and full-length MOZ, acetylation of H4 was incompatible
with binding to PHD1 (Supplementary Figure S1I). PHD2
alone showed strong binding to unmodiﬁed H3 and
H4, but not acetylated H4 peptides, but in contrast to
the composite DPF, PHD2 also showed substantial
binding to peptides containing H3K4me3 (Supplementary
Figures S1I and J). Moreover, no enhanced binding to
H3K14Ac peptides was observed (Supplementary
Figure S1I). This indicates that while PHD2 domain can
interact with the H3 tail, both PHD ﬁngers are required to
set the non-permissive selectivity of MOZ for H3K4me3,
and to stabilize binding to H3K14Ac. Thus, the composite
DPF is required for the ability of MOZ to sample H3K4
methylation and H3K14 acetylation status.
A novel function for MOZ DPF in promoting acetylation
of H3K14 and H3K9
The ability of the MOZ DPF to bind to H3 and H4
N-terminal tails dependent on the modiﬁcation status
suggested that the DPF functions in substrate selection,
and thus might cooperate with the MYST acetyltrans-
ferase domain to promote histone acetylation. Time
course acetylation assays revealed that the initial rate of
acetylation of core histones by DPF-MYST was at least
8-fold faster than the MYST domain alone (Figure 1D).
Peptide acetylation assays conﬁrmed that the DPF-MYST
construct can acetylate the H3 N-terminus (1–21), and
immunoblots using H3 acetylation-speciﬁc antibodies
conﬁrmed substantial increases in acetylated H3K9 and
H3K14 in the presence of GST-MOZ DPF-MYST, but
not GST control (Figure 1E). Moreover, pre-acetylation
of H3 at H3K9 and H3K14 resulted in substantially
reduced or negligible levels of acetylation, respectively,
as compared with unmodiﬁed H3 peptide, conﬁrming
that H3K14 and H3K9 are MOZ acetylation targets
(Figure 1F).
The DPF-MYST construct was also capable of
acetylating the H4 N-terminal tails but not H3 (21–44)
(Figure 1G). Remarkably, H3 peptides containing
H3K4me3 were not capable of being acetylated by DPF-
MYST (Figure 1G), despite the availability of unmodiﬁed
H3K9 and H3K14. In contrast, H3K9me3 showed only a
partially reduced level of acetylation compared with
unmodiﬁed H3 (1–21), owing to the availability of
H3K14 for acetylation. These results highlight the key
role of H3K4 in regulating the formation of MOZ/H3
complexes, and identify H3K14 and H3K9 as acetylation
targets of MOZ. To investigate the effect of H3 acetyl-
ation on recruitment of the DPF-MYST, binding assays
were performed in the presence of acetyl CoA. As shown
in Figure 1H, acetyl CoA enhanced the binding of GST-
DPF-MYST to immobilized H3 tail peptide, indicating
that acetylation of the H3 N-terminal tail stabilizes the
interaction of MOZ and H3. These results support the
hypothesis that the MOZ DPF functions in binding
to H3, thus facilitating its acetylation. In contrast,
trimethylation of H3K4 prevents interaction of MOZ
with H3 and hampers H3K14/K9 acetylation.
The MOZ DPF induces a unique a-helical conformation
in the H3 tail
To understand the molecular basis of H3 recognition by
MOZ and the consequences of H3K9 and H3K14 acetyl-
ation,wedetermined crystal structures spanningMOZDPF
(194–323) alone and in complex with a series of histone
H3 peptides (1–21), unmodiﬁed or acetylated at H3K9 or
H3K14 to 3.0 A˚, 1.6 A˚, 1.6 A˚ and 2.5 A˚ resolutions, respect-
ively. The DPF–H3 complex structure was solved by SAD
using the anomalous signal from the zinc atoms and served
as a search model in the structure determination of the
DPF in isolation and in complex with H3K9ac and
H3K14ac by molecular replacement. Data collection
and reﬁnement statistics are summarized in Table 1.
The structure of MOZ DPF shows the typical globular
domain of a DPF with PHD1 and PHD2 each harbouring
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two zinc atoms coordinated by C4-H-C3 motifs in cross-
brace topology (Figure 2A). In our structures, residues
L194–D199 at the N-terminal boundary of PHD1 form
a helix (denoted as a1) that folds back onto the DPF
core and interacts with the PHD2 subdomain through
salt bridge interactions between E197 and R286, hydro-
phobic contacts engaging L194 and I309 and interactions
between the H196 and R269 side chains (Figure 2A).
Other interactions between the PHD1 and PHD2 subdo-
mains are observed, including a hydrogen bond between
W257 and D285 (Figure 2A). On H3 binding, subtle con-
formational changes in the DPF domain occur in regions
of direct contact with H3, including a side chain rotation
of F280 and changes in a linker region (designated L1),
which harbours a helical turn in the H3 complex (A275-
Figure 3. Structural basis of H3, H3K9ac and H3K14ac recognition by
MOZ. Surface representation of the MOZ DPF domain coloured ac-
cording to electrostatic potential in complex with unmodiﬁed H3
(middle), H3K9ac (top) and H3K14ac (bottom) in red cartoon repre-
sentation. Please note the exposed position of the H3K9 side chain, the
preservation of the helical conformation that is independent of acetyl-
ation of either K9 or K14 and the GG hinge that mediates conform-
ational changes to allow K14ac to bind to a pocket on the DPF
domain.
Figure 2. Structure of the MOZ DPF domain. (A) Crystal structure of
MOZ DPF spanning residues L194-G316 with the zinc atoms shown as
grey spheres and the secondary structure elements indicated. The PHD1
and PHD2 subdomains are coloured in turquoise and blue, respectively.
Residues engaged in interactions with the N-terminal helix a1 and
PHD2 as well as a direct hydrogen bonding interaction between
PHD1 and PHD2 are labelled and shown in stick representation.
(B) Superposition of ribbon representations of the unbound MOZ
DPF domain (blue) and the MOZ DPF domain as observed in
complex with unmodiﬁed H3 (light blue); H3 is not shown for
clarity. Key residues that undergo conformational changes are shown
in stick representation and are labelled. Note that PHD2 is more
affected by the interaction with H3 with larger changes on binding
observed. Linker L1 that precedes b3 is partly disordered and the
H3K4 binding pocket is partially occluded in the unbound structure.
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N277; labelled as a3a in Figure 2B) but not in the
unbound DPF structure.
Unexpectedly, the H3 tail adopts extensive a-helical con-
formation in complex with MOZ DPF (Figures 3 and 4;
Supplementary Figure S4A) in contrast to the extended
conformation of H3 peptides observed in other complexes
(see Figure 5E). This helix encompasses residues H3K4-
T11 and spans across the DPF domain (Figure 3). As a
consequence, these residues occupy different spatial pos-
itions with side chains of H3K4, H3A7, H3R8 and
H3T11 protruding from one side of the helix, while the
H3Q5, H3T6, H3K9 and H3S10 side chains occupy the
opposite side (Figures 3, 4C and D; Supplementary
Figure S3A). Overall, the MOZ DPF-H3 interface area is
characterized by distinct binding pockets that exhibit
negative electrostatic potential (Figure 3) to accommodate
the positively charged H3 lysine and arginine residues.
Hydrogen bonds and salt bridges dominate the interface
although hydrophobic interactions also contribute
(Figure 4A and C; Supplementary Figure S4C). The side
chain of H3A1 inserts into a hydrophobic pocket formed
by residues M300, P301 and W305 while the N-terminal
amine forms a hydrogen bond with the main chain
carbonyl of G303 (Supplementary Figure S4C). H3R2
engages in a network of hydrogen bonding and electrostatic
interactions with two aspartate residues, D282 and D285,
the main chain carbonyl of C281 and the main chain amine
of F280 (Supplementary Figure S4C). H3T3 forms hydro-
phobic contacts with L279 and M300 and the hydroxyl
group forms a hydrogen bond with D276 in the a3a helix
induced by complex formation (Figure 4C; Supplementary
Figure S4C).
The side chain of H3K4 inserts into a pocket on the
surface of MOZ DPF (Figures 3 and 4C) that is partially
occluded by residues from the L1 linker in the unbound
DPF crystal structure (Figure 2B). Interestingly, H3K4
engages in direct hydrogen bonding interactions with the
main chain carbonyls of I260, E261 and K263
(Figure 4A), an atypical binding mode for H3K4 in com-
parison with other PHD complexes that was also not
observed using the shorter construct (18). A water
molecule also coordinates the Ne-amino group and hydro-
phobic contacts occur between A275 and H3K4. H3R8
also protrudes towards the H3K4 pocket (Figure 4A and
C), with the guanidinium group forming salt bridge inter-
actions with E261. In addition, the main chain amine of
H3Q5 forms a hydrogen bond with the carbonyl group of
A275, whereas H3A7 forms hydrophobic contacts with
I260 and F280. The main chain carbonyl of H3S10
engages in a hydrogen bond with K243. Finally, H3T11
occupies a hydrophobic pocket formed by F211, L242,
I260 and K243. H3G12 and H3G13 break the alpha
helical conformation (Figure 4C). No interpretable
density is visible beyond H3G13, indicating that H3
residues 14–21 are ﬂexible and do not interact with the
DPF domain. The binding mode of H3K4 (Figure 4A)
provides a rationale for the selectivity of MOZ against
H3K4me3, as in addition to the steric implications, the
trimethyl ammonium moiety would be unable to form
hydrogen bonds with the K4 binding pocket. Although
mono- or dimethylated forms of H3K4 would still be
capable of acting as hydrogen bond donors to carbonyl
groups, the reduced binding observed is likely due to steric
effects.
A double-glycine hinge mechanism facilitates H3K14ac
docking with the DPF
In this novel H3 binding mode, the side chains of H3Q5,
H3T6, H3K9 and H3S10 may be amenable to modiﬁcation
by other histone modifying enzymes. In particular, the side
chain of H3K9 is orientated away from the DPF in a
position ideal to allow its modiﬁcation, e.g. acetylation
by the MYST domain, consistent with our data
(Figure 1D and E) and other studies (25,26). Based on
the biochemical assays (Figure 1C) and our MOZ DPF–
H3 complex structure (Figure 3) we reasoned that H3K9
modiﬁcation would have little impact on the helical struc-
ture of the N-terminal tail in complex with MOZ. To test
this hypothesis, we crystallized the MOZ DPF with a
peptide harbouring an acetylation modiﬁcation on H3K9.
The structure conﬁrmed our hypothesis and shows that the
side chain of H3K9ac is highly ﬂexible consistent with its
location pointing away from the DPF domain, while the
helical conformation of the tail is preserved (Figure 3;
Supplementary Figure S3B).
To investigate the impact of H3K14ac on the helical
structure of the H3 tail, we crystallized a MOZ DPF–
H3K14ac complex. The structure revealed that the
helical conformation of H3K4-T11 is preserved
(Figure 3; Supplementary Figure S4B) and the majority
of interactions in this region of H3 are unaltered.
However, the interface area (844.6 A˚2) is increased in com-
parison with the DPF-H3 structure (695 A˚2), revealing
the molecular basis for H3K14ac recognition by MOZ.
Importantly, a conformational change mediated through
H3G12-G13 allows the acetylated H3K14 side chain,
now devoid of charge, to insert into a preformed pocket
on the DPF surface (Figure 3; Supplementary Figures S3C
and S4B). This pocket (lined by S210, F211, N235, L242,
W257, C259 and I260) is mainly hydrophobic and
exhibits a weak positive electrostatic potential, rendering
it unfavourable for unmodiﬁed K14 interaction (Figures 3
and 4D). The acetyl group of H3K14ac forms a hydrogen
bond with the main chain amine of I260, revealing that
I260 makes contacts with both H3K14ac and H3K4.
While H3A15 engages in a hydrophobic contact with
L213, residues C-terminal to this are not visible in the
electron density, indicating that they are not involved
in interactions with the DPF domain. The observed struc-
tural changes between H3 and H3K14ac in complex
with the DPF reveal a mechanism for modulating H3
interactions with MOZ. To validate the requirement of
the double glycine (GG) hinge for docking of H3K14Ac,
we used a H3 peptide in which G12 and G13 were
substituted with alanine residues. As shown in
Figure 4E, while MOZ-DPF showed enhanced binding
to the H3K14ac peptide as compared with unmodiﬁed
H3 tail, this enhanced interaction was not observed
using the GG12/13AA peptide, which bound the DPF to
a similar level as unmodiﬁed H3. This result highlights
the importance of the GG hinge to enable engagement
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of the H3K14Ac by MOZ. The results also suggest for the
ﬁrst time a functional role for H3 tail residues G12 and
G13 in epigenetic signalling.
H3 tail recognition by MOZ and DPF3b/BAF45c
Aside from MORF, the MOZ DPF domain shares
sequence homology with the BAF45 proteins (also known
as DPF1–3) (Figure 5D), which are key components of
the mammalian Switch/Sucrose Non fermentable (SWI/
SNF) or BAF complexes (27). The DPF domain of
DPF3b/BAF45c [Root Mean Square Deviation
(RMSD)=1.9 A˚; Z score=13.7; sequence identity of
52% (28)] is the only other DPF domain for which both
unmodiﬁed H3 and H3K14ac complex structures are cur-
rently available for comparison (15). While the MOZ
Figure 4. Interactions of H3 and H3K14ac with the MOZ DPF. (A, B) Close up view of complex crystal structures in stick representation,
highlighting the interactions with key residues labelled; blue denotes for MOZ DPF residues and red for H3 or H3K14ac. The DPF–H3 complex
is shown in (A) and the DPF–H3K14ac complex in (B). Plausible hydrogen bonding interactions are indicated by dashed lines. Zinc atoms are shown
as grey spheres. (C) H3 N-terminal tail structure as seen in the complex with MOZ DPF and (D) H3K14ac structure as seen in the complex with
MOZ DPF depicted in red. Binding pockets on the DPF surface are schematically indicated as blue crescents. Corresponding interacting residues
involved in hydrogen bonding interactions (dark blue) or hydrophobic contacts (light blue) are indicated. (E) Binding of GST-MOZ DPF to histone
H3 tail peptides as indicated, i.e. unmodiﬁed H3, H3K14ac or H3K14ac peptide in which the GG hinge is mutated. Two exposures are shown (2 or
5 s) to highlight the differential binding.
830 Nucleic Acids Research, 2014, Vol. 42, No. 2
 by guest on M
arch 23, 2014
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
structure contains an additional N-terminal helix (a1),
DPF3b contains an extra helix at its C-terminus
(Figure 5B). The N-terminal anchor of H3 (residues
A1-R2-T3) adopts similar conformations in both MOZ
and DPF3b structures. However, a major difference arises
in the way H3K4 is recognized. H3K4 forms hydrogen
bonds/salt bridges with two acidic residues in DPF3b,
E315 (E261 in MOZ DPF) and D328 (whose counterpart
is A275 in MOZ) (Figure 5C) as opposed to interactions
with main chain carbonyls in MOZ. In addition, the L1
region in DPF3b is shorter by one residue. Strikingly,
none of the reported DPF3b complex structures reveal
any helical conformation of H3 peptides (Figure 5B) (15).
As a consequence, H3K9 protrudes into the H3K4 pocket
by interacting with E315 in DPF3b, whereas H3R8
occupies this position in the MOZ complexes (Figure 5C).
While H3 residues 4–13 adopt entirely different
conformations and engage in different contacts with MOZ
and DPF3b, H3K14ac occupies equivalent binding pockets,
albeit involving different interactions (Figure 5C). In
DPF3b, H3K14ac Ne forms a hydrogen bond with the
side chain of D263 (PDB code 2KWJ) (15). In the MOZ–
DPF complex, H3K14ac is within hydrogen bonding
distance of MOZ I260, and engages in van der Waals
contacts with S210 at the rim of the pocket. MOZ N235
and R289 in DPF3b occupy equivalent positions and both
engage in hydrophobic contacts with H3K14ac. Thus, while
the acetylated H3K14 occupies equivalent pockets within
the PHD1 moieties of MOZ and DPF3b, different inter-
actions are used to achieve this (Figure 5C). The alternative
conformations of the H3 tail may reﬂect functional differ-
ences betweenDPF3b andMOZ.UnlikeMOZ andMORF,
BAF45/DPF proteins are not known to harbour any intrin-
sic enzymatic activity, and thus may function uniquely as
histone PTM ‘reader’ components that can tether BAF
complexes to appropriate chromatin targets. MOZ on the
other hand, imposes a structural conformation on the H3
tail to facilitate its acetylation. This ability of MOZ to ma-
nipulateH3 tail conformation reﬂects its dual role in reading
and modifying histone codes to drive developmental gene
expression in haematopoietic and other tissues.
DISCUSSION
While chromatin-associated proteins are clearly essential
components of normal gene regulatory systems, relatively
Figure 5. Comparison of MOZ DPF–H3 with other PHD–H3 complexes. (A) Superposition of MOZ DPF (blue; semi-transparent) in complex with
H3 (brown) and H3K14ac (red). The GG hinge region that mediates the insertion of K14ac into the respective binding pocket is highlighted in
yellow. (B) Superposition of DPF3b in complex with unmodiﬁed H3 [PDB code: 2KWK (15)] and with H3K14ac [PDB code: 2KWJ (15)] depicted
in same colour coding. In the DPF3b complex structures, the H3 conformation is extended. (C) Close up view of a superposition between MOZ
DPF–H3K14ac (blue; red) and DPF3b–H3K14ac (grey; beige) (D) Sequence alignment with MOZ DPF with other DPF domain proteins. Secondary
structure elements observed in our structures are shown above the alignment and MOZ residues that are engaged in H3 recognition are highlighted.
Light blue denotes residues involved in H3R2 interactions, yellow for H3K4 and orange for H3K14ac interactions. Residues engaged in other
interactions are depicted in grey. Colour coding is the same for DPF3b. (E) Comparison of H3 conformations in complex with assorted PHD
domains. Cartoon representations of a number of DPF and PHD domains depicted in blue and H3 tail peptides depicted in red. From left to right:
MOZ DPF-H3; UHRF1-H3 {PDB code 3ASK (35); PYGO-BCL9-H3R2me2K4me2 [PDB code: 2VPG; (33)]; BRPF2-H3 [PDB code: 2L43; (45)];
BHC80-H3 [PDB code 2PUY; (46)]; ING5-H3K4me3 [PDB code 3C6W; (47)}. Circled is a turn feature in the linker region L1 that may contribute
to induction of helical conformation in H3 when interacting with PHD domains such as seen in MOZ, UHRF1 and potentially PYGO-BCL9.
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little is known of their impact on chromatin/histone
structure.
Early observations from the Grunstein and Wolffe
groups predicted that histone tails would adopt helical
conformations when participating in macromolecular
interactions (29,30). Helical propensity of the H3 tail is
also detected by secondary structure prediction algo-
rithms. However, until now, structural studies
investigating H3 tail interactions with chromatin readers
have generally observed extended conformations of the
histone tail. A commonly observed binding mode
involves the formation of antiparallel beta sheets
between single PHD domains and H3 N-terminal
residues (31,32), as seen in bromodomain PHD ﬁnger
2(BRPF2), BRAF35 HDAC Complex protein (BHC80)
and inhibitor of growth family member 5 (ING5)
complexes (Figure 5E). The predominantly helical H3
conformations seen in complex with MOZ DPF
reported in this study are at present unique. This more
compact conformation, in conjunction with a GG hinge,
allows MOZ DPF to engage at least the ﬁrst 15 residues of
the K14 acetylated H3 tail. This H3 binding mode not
only enables MOZ to sample multiple H3 PTMs, but
also facilitates acetylation of H3, providing that the
H3K4me3 mark is absent.
In comparison, single PHD domains typically recognize
up to nine residues of an extended H3 tail (16). However,
on close inspection of available structures, we noticed in-
dications of potential helicity in a subset of H3 complex
structures (Figure 5E). H3 residues 4–5 in complex with
the PHD domain of Pygopus-BCL9 [PDB code: 2VPG,
(33); Figure 5E] closely mimic the start of a helical turn
and this is also seen in a double chromodomain H3
complex (PDB code: 2B2T) (34). Recently a single
helical turn has been observed in complex with the PHD
domain of the E3 ubiquitin ligase UHRF1 [PDB code
3ASK (35); Figure 5E]. Thus we noted that helical pro-
pensity of the H3 tail in these complexes appeared to cor-
relate with differences in the L1 linker sequences of the
reader module. A helical turn or loop in longer L1 linkers
(such as a3a in MOZ; circled in Figure 5E) may induce a
degree of helicity by ‘bending’ H3 tails. Alternatively,
shorter L1 regions probably favour antiparallel sheet for-
mation such as seen for BRPF2 (Figure 5E). These obser-
vations lead us to speculate that the L1 linker region may
inﬂuence H3 conformation as highlighted in Figure 5E.
Thus, partially helical conformations of the H3 tail may
also be a feature of its recognition by other histone-
binding domains awaiting structure elucidation.
Our structures provide novel insight into histone tail
PTM sampling by a chromatin reader. Binding of MOZ
DPF to the H3 tail is diminished by H3K4me3
(Figure 1B), but enhanced by H3 acetylation (Figure 1B
and C), and the structures show the molecular detail of
how H3K14 acetylation promotes further contacts within
the complex through conformational changes in H3
(Figures 3 and 5A). A recently reported structure of a
shorter MOZ DPF construct (residues 202–313) bound
to H3 residues 1–7 (18) agrees with our ﬁndings with
regard to how residues H3 A1-T3 engage with MOZ.
However, the absence of the sequence comprising a1
helical region in the truncated MOZ DPF, and occupation
of the H3K14Ac binding pocket by acetate from the crys-
tallization conditions are likely to account for the other-
wise major differences in H3 contacts observed, including
the lack of helical structure in the H3 tail (Supplementary
Figure S5).
While our structures reveal how acetylation of the H3
tail at K14 can stabilize the interaction with MOZ,
acetylated H4 tail peptides failed to bind MOZ in
in vitro binding assays (Figure 1B; Supplementary
Figure S1G). These results suggest opposing effects of
H3 and H4 acetylation on their interactions with MOZ
as summarized in Figure 6. The orientation of H3K9
protruding away from the DPF domain suggests it is ‘pre-
sented’ for modiﬁcation by the intrinsic MYST catalytic
domain or other enzymes such as H3K9
methyltransferases present in MOZ complexes (36). We
have also shown that acetylation of H3K9 does not
impact on the H3 conformation observed in complex
with the DPF domain. Similarly, the unique conformation
of the H3 tail in complex with MOZ suggests that H3T6,
H3R8, H3S10 or H3T11 may also be amenable to PTM
sampling or poised for modiﬁcation (Figure 4C and D).
In the unmodiﬁed H3-DPF complex, the region C-
terminal to H3G13, including H3K14, is not in contact
with the DPF and is therefore also potentially available
for acetylation by the MOZ MYST domain. The
acetylated H3K14 can dock with the MOZ DPF, as a
consequence of the structural ﬂexibility of the preceding
GG hinge (Figure 5A) as conﬁrmed by the binding assay
showing that the GG hinge is required for enhanced
binding of MOZ to H3K14Ac (Figure 4E). Interestingly,
other GG motifs are present in the N-terminal tails of the
core histones, where they may perform similar functions
as structural ‘hinges’. These GG motifs also ﬂank lysine
residues that are important regulatory targets in chroma-
tin such as H3K36, H4K8, H4K16 and H2AK9.
Interestingly, mutations in the G34 residue in H3.3
variant histones have been discovered as key drivers in
glioblastomas, although how this impacts on chromatin
modiﬁcation/remodelling remains to be determined
(37,38). Thus, as in the case of MOZ and H3K14 acetyl-
ation, GG hinges may facilitate alternate conformations
that modulate histone tail interactions with other chroma-
tin regulators.
Our data reveal a role for MOZ DPF in selection of
histone substrates for acetylation. While the MOZ
MYST domain acetylates both H3 and H4 substrates
in vitro, the rate of H3 acetylation is strongly enhanced
by the presence of the DPF domain (Figure 1D). MOZ
acetylates both H3K14 and H3K9 in vitro (Figure 1E and
F) consistent with a report that ING5/MOZ/MORF
complexes acetylate both H3 and H4 acetylation, and in
particular target H3K14 (25). Interestingly, a recent study
reported signiﬁcant coincidence of H3K9ac and H3K14ac
marks across the genome of ES cells, and showed that
both modiﬁcations are associated with the promoters
and enhancers of actively transcribed genes (39). The
study also reported that H3K14ac marks a subset of
genes that are poised for activation. ChIP-Seq studies
will be required to identify MOZ binding sites across the
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genome and to assess whether these are enriched in
H3K14ac or other histone PTMs. Such studies will help
establish how composite PTMs can transduce their down-
stream functions.
The inability of MOZ to bind H3K4me3 correlates with
its failure to acetylate H3K4me3 peptides (Figure 1G).
Methylation of H3K4 plays a central role in the regulation
of gene expression, as H3K4me3 is enriched within tran-
scriptionally active regions of the genome. Trimethylation
of H3K4 is catalysed by Mixed lineage leukaemia (MLL)
complexes, which also contain the MYST family protein
males absent on the ﬁrst (MOF), responsible for H4K16
acetylation (40,41), and the combination of these PTMs
promotes recruitment of the promotes recruitment of the
nucleosome remodelling factor (NURF) chromatin
remodelling complex. Interestingly, the BPTF subunit of
the NURF complex binds efﬁciently to H3K4me3 and
H4K16ac via its PHD and bromodomains, respectively
(5), thus showing opposing histone binding preferences
to the DPF domains of MOZ and MORF. However,
MOZ and MORF can associate with complexes contain-
ing ING5 and BRPF1/2/3 proteins (42,43), which bind
H3K4me3 and unmodiﬁed H3, respectively. Such differ-
ential binding speciﬁcities within multiprotein complexes
may further facilitate co-regulator exchange on chroma-
tin, as a consequence of sequential manipulation and
recognition of histone PTMs.
Despite their sequence and structural similarity, MOZ
and DPF3b exhibit major differences in how they recog-
nize H3. Sequence variations in the H3K4 pocket are
likely to be responsible for the different H3K4 binding
modes (Figure 5C and D). Our results also indicate that
acetylation has differential effects on binding of H4 to
MOZ and DPF3b. DPF3b was reported to bind H4 tail
peptides weakly compared with H3 peptides, although
binding to H4 was reported to be substantially increased
following K16 acetylation (15). In our hands, the rela-
tively weak binding of MOZ DPF to H4 tail peptides
was prevented by single or multiple acetylation at K5,
K8, K12 or K16 (Figure S1G). Thus, high levels of
acetylated H4 in our core histone preparations may also
contribute to failure to detect H4 binding to MOZ in vitro
(Supplementary Figure S1B).
The residence of MOZ, MORF and other epigenetic
regulators in large macromolecular complexes provides a
plausible model for how dynamic PTM signalling could be
achieved through sequential binding and release of chro-
matin recognition modules and associated enzymatic
domains within the complex. By sequential modiﬁcation
of H3 and H4 substrates, MOZ might dictate its own resi-
dency on chromatin, in combination with other chromatin
regulators as summarized in Figure 6. Our ﬁndings that
MOZ signiﬁcantly alters H3 tail conformation to sample
and modify the histone code provides new insight into
these functions of chromatin regulators. The successful
targeting of epigenetic regulators by small molecules in
preclinical models of leukaemia (44,48,49), underlines
the potential for translating chromatin biology into new
therapeutic strategies. Thus, in addition to uncovering
novel aspects of chromatin regulator function, our
ﬁndings will aid the development of targeted strategies
for MOZ-associated leukaemias.
Figure 6. (A) Histone PTM sampling by MOZ. Schematic representation showing the recruitment of MOZ proteins to chromatin through complex
formation with transcription factors (TFs) or by direct interaction of MOZ with histones. Unmodiﬁed H3 and H4 tails, or modiﬁcations such as
H3K9ac or H3K9me3 are permissive for MOZ recruitment. MOZ recruitment is reinforced by H3K14 acetylation. However, H3K4me3 or H4 tail
acetylation constitutes non-permissive PTMs that may repulse MOZ from chromatin. (B) Histone acetylation by MOZ regulates its occupancy on
chromatin. PTM sampling by the MOZ DPF facilitates histone substrate selection for acetylation. Acetylation of H3K14 stabilizes residency of MOZ
on chromatin, whereas acetylation of H4 by MOZ or other regulators is non-permissive for MOZ recruitment. Histone PTMs generated by other
factors such as the MLL histone methyltransferase complex that catalyses H3K4 trimethylation, also impact on MOZ residency. Thus, chromatin
modifying proteins generate ‘Hire’ and ‘Fire’ PTM signatures that regulate their interactions with chromatin.
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ACCESSION NUMBERS
Model coordinates and structure factor ﬁles were
deposited under accession codes 4LJN (MOZ DPF),
4LK9 (MOZ DPF in complex with H3), 4LKA (MOZ
DPF in complex with H3K9ac) and 4LLB (MOZ DPF
in complex with H3K14ac) in the Protein Data Bank.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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